Wagstaff, J., Wolchok, J. D., Chiarion-Sileni, V., Gonzalez, R., Grob, J., Rutkowski, P., . . . Hodi, F. S. (2022). Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. Journal of Clinical Oncology, 40(2), pp. 127-137. doi:10.1200/jco.21.02229

Wagstaff, John, et al. "Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma." Journal of Clinical Oncology 40, no. 2 (2022): 127-137.

Wagstaff, John, et al. "Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma." Journal of Clinical Oncology 40.2 (2022): 127-137.